| KIN Market Cap History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the KIN market cap history going back to 12/12/2013:
Also see: KIN Shares Outstanding History and KIN YTD Return |
KIN Market Cap History — Kindred Biosciences Capitalization Over Time
As of 7/31/2021 Kindred Biosciences has a market cap of 414.62 million. Investors often follow the KIN market cap history to compare the size of the company over time.
This page shows KIN market capitalization trends over time, with 35 market cap datapoints presented, dating back to 12/12/2013.
| KIN Market Cap History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
KIN Historical Market Cap: +13.38% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| KIN Stock Price Chart |
| About Kindred Biosciences Inc |
| Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets. Co.'s portfolio includes: Mirataz®, which is its transdermal drug for the management of weight loss in cats; and Zimeta™, which is for the control of pyrexia in horses. Co.'s product candidates include: KIND-016, a fully caninized monoclonal antibody targeting interleukin-31 for the treatment of atopic dermatitis in dogs; KIND-032, a fully caninized monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; and KIND-025, a canine fusion protein targeting IL-4 and IL-13, for the treatment of atopic dermatitis in dogs. We show 35 historical shares outstanding datapoints in our KIN shares outstanding history coverage, used to compute KIN market cap on those dates. Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing KIN market cap history over the course of time is important for investors interested in comparing KIN's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of KIN versus a peer is one thing; comparing KIN market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like KIN can fluctuate over the course of history. With this page we aim to empower investors researching KIN by allowing them to research the KIN market cap history. |
| KIN Current Stock Quote |
Quotes delayed 20 minutes  Free KIN Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: The Importance of Market Cap | |
|
Video: The Importance of Market Cap
| KIN Share Performance |
| Market Cap Peers |
| Kindred Biosciences (KIN) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:
KLDO Market Cap History KLRS Market Cap History KMPH Market Cap History KND Market Cap History KNTE Market Cap History KOD Market Cap History KOOL Market Cap History KPRX Market Cap History KPTI Market Cap History KRBP Market Cap History More Healthcare companies » |
KIN Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
